{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:06:34Z","timestamp":1792735594228,"version":"4.5.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1038\/nrgastro.2010.219","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T12:06:35Z","timestamp":1296821195000},"page":"69-71","source":"Crossref","is-referenced-by-count":53,"title":["The dawn of a new era in HCV therapy"],"prefix":"10.1038","volume":"8","author":[{"given":"Sandra","family":"Ciesek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,4]]},"reference":[{"key":"BFnrgastro2010219_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nrd2411","volume":"6","author":"MP Manns","year":"2007","unstructured":"Manns, M. P. et al. The way forward in HCV treatment\u2014finding the right path. Nat. Rev. Drug Discov. 6, 991\u20131000 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrgastro2010219_CR2","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","volume":"362","author":"JG McHutchison","year":"2010","unstructured":"McHutchison, J. G. et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292\u20131303 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2010219_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo, P. Y. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705\u2013716 (2010).","journal-title":"Lancet"},{"issue":"Suppl.","key":"BFnrgastro2010219_CR4","first-page":"427A","volume":"52","author":"IM Jacobson","year":"2010","unstructured":"Jacobson, I. M. et al. Telaprevir in combination with Peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study [abstract 211]. Hepatology 52 (Suppl.), 427A (2010).","journal-title":"Hepatology"},{"issue":"Suppl.","key":"BFnrgastro2010219_CR5","first-page":"107A","volume":"52","author":"F Poordad","year":"2010","unstructured":"Poordad, F. et al. Boceprevir (BOC) combined with Peginterferon alfa-2B\/ribavirin for treatment-naive patients with hepatitis C virus (HCV) genotype 1 SPRINT-2 final results. Hepatology 52 (Suppl.), 107A (2010).","journal-title":"Hepatology"},{"key":"BFnrgastro2010219_CR6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","volume":"376","author":"EJ Gane","year":"2010","unstructured":"Gane, E. J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467\u20131475 (2010).","journal-title":"Lancet"},{"key":"BFnrgastro2010219_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1126\/science.1113329","volume":"309","author":"CL Jopling","year":"2005","unstructured":"Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577\u20131581 (2005).","journal-title":"Science"},{"key":"BFnrgastro2010219_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1126\/science.1178178","volume":"327","author":"RE Lanford","year":"2010","unstructured":"Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198\u2013201 (2010).","journal-title":"Science"},{"issue":"6","key":"BFnrgastro2010219_CR9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/gut.2010.217323","volume":"60","author":"H. Patel","year":"2010","unstructured":"Patel, H. & Heathcote, E. J. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3. Gut doi:10.1136\/gut.2010.217323.","journal-title":"Gut"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2010.219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2010.219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2010.219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:41:08Z","timestamp":1684467668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2010.219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["BFnrgastro2010219"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2010.219","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}